Regency Capital Management Inc. DE Has $4.27 Million Position in Danaher Co. (NYSE:DHR)

Regency Capital Management Inc. DE cut its position in shares of Danaher Co. (NYSE:DHR) by 14.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,582 shares of the conglomerate’s stock after selling 3,169 shares during the quarter. Danaher accounts for 2.3% of Regency Capital Management Inc. DE’s portfolio, making the stock its 19th biggest holding. Regency Capital Management Inc. DE’s holdings in Danaher were worth $4,265,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Decker Retirement Planning Inc. acquired a new stake in shares of Danaher during the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher in the 3rd quarter valued at $40,000. FSA Wealth Management LLC acquired a new position in shares of Danaher in the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Danaher during the 3rd quarter valued at about $55,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Shares of DHR stock opened at $245.95 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70. The firm has a market cap of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The stock has a 50-day moving average price of $235.33 and a 200 day moving average price of $253.45.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analyst Ratings Changes

DHR has been the subject of a number of analyst reports. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Raymond James cut their target price on Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research report on Tuesday, January 21st. UBS Group dropped their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Citigroup reduced their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Finally, Royal Bank of Canada cut their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.